The New York-based AI biotech will use its AMICA-OS platform to analyze clinical immune data for BMS, aiming to inform patient stratification, biomarkers, and trial decisions. | Read More in JPost.com – Business & Innovation | The Jerusalem Post.   Read More in Israel NOWlej.